Slingshot members are tracking this event:
Merck’s KEYTRUDA (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Jun 16, 2016
- Discussing the NSCLC landscape after KEYNOTE-189 data, specifically PD-1 combo programs MRK, ARMO, NKTR Executed On: Apr 30, 2018 at 10:00 AM EDT
Related Keywords Keytruda, Chemotherapy, Non-small Cell Lung Cancer, Keynote-024, Pembrolizumab, Pd-l1